Kedalion Therapeutics, a clinical-stage ophthalmic drug company based in Menlo Park, CA, has developed AcuStream technology that delivers topical drugs to the eye with comparable efficacy using 80% less dose than standard drops. This technology also improves the side effect profile and enhances patient comfort and convenience following self-administration. By reducing side effects and the burden on the healthcare system, Kedalion's technology offers healthcare professionals the ability to provide more comfort and convenience to patients.